Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort.

Bartha I, Assel M, Sloot PM, Zazzi M, Torti C, Schülter E, De Luca A, Sönnerborg A, Abecasis AB, Van Laethem K, Rosi A, Svärd J, Paredes R, van de Vijver DA, Vandamme AM, Müller V.

BMC Infect Dis. 2013 Nov 12;13:537. doi: 10.1186/1471-2334-13-537.

2.

Therapy failure resulting from superinfection by a drug-resistant HIV variant.

Pingen M, Nouwen JL, Dinant S, Albert J, Mild M, Brodin J, Simen BB, Walsh S, Kayser M, van der Ende ME, Schutten M, Boucher CA.

Antivir Ther. 2012;17(8):1621-5. doi: 10.3851/IMP2267. Epub 2012 Jul 31.

PMID:
22846173
3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.

de Mulder M, Yebra G, Martín L, Prieto L, Mellado MJ, Rojo P, Muñoz-Fernández MÁ, Jiménez de Ory S, Ramos JT, Holguín A; Madrid cohort of HIV-infected children..

J Antimicrob Chemother. 2011 Oct;66(10):2362-71. doi: 10.1093/jac/dkr305. Epub 2011 Aug 2.

PMID:
21810838
5.

Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.

Yaotsè DA, Nicole V, Roch NF, Mireille PD, Eric D, Martine P.

Infect Genet Evol. 2009 Jul;9(4):646-52. doi: 10.1016/j.meegid.2009.04.002. Epub 2009 Apr 15.

PMID:
19460333
6.

Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.

de Mulder M, Yebra G, Navas A, Martin L, de Jose MI, Navarro ML, de Ory SJ, Gonzalez-Granado I, Mellado MJ, Ramos JT, Holguin A.

Pediatr Infect Dis J. 2012 Nov;31(11):e213-21. doi: 10.1097/INF.0b013e3182678c7c.

PMID:
22785049
7.

Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008.

Callegaro A, Svicher V, Alteri C, Lo Presti A, Valenti D, Goglio A, Salemi M, Cella E, Perno CF, Ciccozzi M, Maggiolo F.

Infect Genet Evol. 2011 Apr;11(3):624-32. doi: 10.1016/j.meegid.2011.01.019. Epub 2011 Feb 1.

PMID:
21292031
8.

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8. Epub 2005 Apr 12.

9.
10.

HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.

Elmi Abar A, Jlizi A, Darar HY, Kacem MA, Slim A.

Diagn Pathol. 2012 Oct 8;7:138. doi: 10.1186/1746-1596-7-138.

11.

Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.

Ceccarelli L, Salpini R, Moudourou S, Cento V, Santoro MM, Fokam J, Takou D, Nanfack A, Dori L, Torimiro J, Sarmati L, Andreoni M, Perno CF, Colizzi V, Cappelli G.

J Med Virol. 2012 May;84(5):721-7. doi: 10.1002/jmv.23244.

PMID:
22431019
12.

A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection.

Pernas M, Casado C, Fuentes R, Pérez-Elías MJ, López-Galíndez C.

J Acquir Immune Defic Syndr. 2006 May;42(1):12-8.

PMID:
16763489
13.

Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection.

Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, Wainberg MA; Co-Investigators of the Quebec Primary Infection Study..

AIDS. 2004 Aug 20;18(12):1653-60. Erratum in: AIDS. 2004 Oct 21;18(15):2107.

PMID:
15280776
14.

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.

PMID:
15170628
15.

Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.

Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P, Machado E, de Sá CA, Eyer-Silva WA, Sion FS, Passioni LF, Menezes JA, Calazans AR, Tanuri A.

Virology. 2000 Sep 15;275(1):107-15.

16.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA..

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
17.

Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.

Bellocchi MC, Forbici F, Palombi L, Gori C, Coelho E, Svicher V, D'Arrigo R, Emberti-Gialloreti L, Ceffa S, Erba F, Marazzi MC, Silberstein FC, Perno CF.

J Med Virol. 2005 Aug;76(4):452-8.

PMID:
15977236
18.

Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.

Kijak GH, Simon V, Balfe P, Vanderhoeven J, Pampuro SE, Zala C, Ochoa C, Cahn P, Markowitz M, Salomon H.

J Virol. 2002 Jul;76(14):7000-9.

19.

Phylogenetic internal control for HIV-1 genotypic antiretroviral testing.

Boeri E, Canducci F, Grasso MA, Presi S, Carrera P, Racca S, Clementi M.

New Microbiol. 2004 Apr;27(2 Suppl 1):105-9.

PMID:
15646072
20.

Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy.

Vergne L, Kane CT, Laurent C, Diakhaté N, Gueye NF, Gueye PM, Sow PS, Faye MA, Liégeois F, Ndir A, Lanièce I, Peeters M, Ndoye I, Mboup S, Delaporte E.

AIDS. 2003 Jul;17 Suppl 3:S31-8.

PMID:
14565607

Supplemental Content

Support Center